Search
02/06/2022
A Randomized Clinical Trial to Evaluate the Effects of Safinamide on Apathetic Non-demented Patients With Parkinson's Disease
Kulisevsky, J, Martinez-Horta, S, Campolongo, A, Pascual-Sedano, B, Marin-Lahoz, J, Bejr-kasem, H, Aracil-Bolanos, I, Horta-Barba, A, Puig-Davi, A, Pagonabarraga, J. A Randomized Clinical Trial to Evaluate the Effects of Safinamide on Apathetic Non-demented Patients With Parkinson's Disease. Frontiers in Neurology. 2022; 13DOI:10.3389/fneur.2022.866502. PMID:35720066. IF:3.400(Q2/5D).
02/06/2022
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort
Tam, CS, Allan, JN, Siddiqi, T, Kipps, TJ, Jacobs, R, Opat, S, Barr, PM, Tedeschi, A, Trentin, L, Bannerji, R, Jackson, S, Kuss, BJ, Moreno, C, Szafer-Glusman, E, Russell, K, Zhou, C, Ninomoto, J, Dean, JP, Wierda, WG, Ghia, P. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. BLOOD. 2022; 139(22)DOI:10.1182/blood.2021014488. PMID:35196370. IF:20.300(Q1/1D).
01/06/2022
Identification of serum microRNAs as potential biomarkers in Pompe disease (vol 6, pg 1214, 2019)
Carrasco-Rozas, A, Fernandez-Simon, E, Lleixa, MC, Belmonte, I, Pedrosa-Hernandez, I, Montiel-Morillo, E, Nunez-Peralta, C, Rossello, JL, Segovia, S, De Luna, N, Suarez-Calvet, X, Illa, I, Diaz-Manera, J, Gallardo, E, Barba-Romero, MA, Barcena, J, Carzorla, MR, Creus, C, Coll-Canti, J, Diaz, M, Dominguez, C, Torron, RF, Antelo, MJG, Grau, JM, Caravaca, MTG, Hernandez, JCL, de Munain, AL, Martinez-Garcia, FA, Morgado, Y, Moreno, A, Moris, G, Munoz-Blanco, MA, Nascimento, A, Paradas, C, Pozo, JLP, Querol, L, Robledo-Strauss, A, Garcia, RR, Rojas-Marcos, I, Salazar, JA, Uson, M. Identification of serum microRNAs as potential biomarkers in Pompe disease (vol 6, pg 1214, 2019). Annals of Clinical and Translational Neurology. 2022; 9(6)DOI:10.1002/acn3.51600. PMID:31353854. IF:5.300(Q1/2D).
01/06/2022
Frequency and clinical correlates of anti-nerve antibodies in a large population of CIDP patients included in the Italian database
Liberatore, G, De Lorenzo, A, Giannotta, C, Manganelli, F, Filosto, M, Cosentino, G, Cocito, D, Briani, C, Cortese, A, Fazio, R, Lauria, G, Clerici, AM, Rosso, T, Marfia, GA, Antonini, G, Cavaletti, G, Carpo, M, Doneddu, PE, Spina, E, Piccinelli, SC, Peci, E, Querol, L, Nobile-Orazio, E. Frequency and clinical correlates of anti-nerve antibodies in a large population of CIDP patients included in the Italian database. NEUROLOGICAL SCIENCES. 2022; 43(6)DOI:10.1007/s10072-021-05811-0. PMID:35048233. IF:3.300(Q2/5D).
01/06/2022
Three-year quantitative magnetic resonance imaging and phosphorus magnetic resonance spectroscopy study in lower limb muscle in dysferlinopathy
Reyngoudt, H, Smith, FE, Araujo, ECD, Wilson, I, Fernandez-Torron, R, James, MK, Moore, UR, Diaz-Manera, J, Marty, B, Azzabou, N, Gordish, H, Rufibach, L, Hodgson, T, Wallace, D, Ward, L, Boisserie, JM, Le Louer, J, Hilsden, H, Sutherland, H, Canal, A, Hogrel, JY, Jacobs, M, Stojkovic, T, Bushby, K, Mayhew, A, Straub, V, Carlier, PG, Blamire, AM. Three-year quantitative magnetic resonance imaging and phosphorus magnetic resonance spectroscopy study in lower limb muscle in dysferlinopathy. Journal of Cachexia Sarcopenia and Muscle. 2022; 13(3)DOI:10.1002/jcsm.12987. PMID:35373496. IF:8.900(Q1/1D).
01/06/2022
An Integrative Analysis of DNA Methylation Pattern in Myotonic Dystrophy Type 1 Samples Reveals a Distinct DNA Methylation Profile between Tissues and a Novel Muscle-Associated Epigenetic Dysregulation
Koehorst, E, Odria, R, Capo, J, Nunez-Manchon, J, Arbex, A, Almendrote, M, Linares-Pardo, I, Natera-de Benito, D, Saez, V, Nascimento, A, Ortez, C, Rubio, MA, Diaz-Manera, J, Alonso-Perez, J, Lucente, G, Rodriguez-Palmero, A, Ramos-Fransi, A, Martinez-Pineiro, A, Nogales-Gadea, G, Suelves, M. An Integrative Analysis of DNA Methylation Pattern in Myotonic Dystrophy Type 1 Samples Reveals a Distinct DNA Methylation Profile between Tissues and a Novel Muscle-Associated Epigenetic Dysregulation. Biomedicines. 2022; 10(6)DOI:10.3390/biomedicines10061372. PMID:35740394. IF:4.700(Q1/3D).
01/06/2022
Predictors of the change in burden, strain, mood, and quality of life among caregivers of Parkinson's disease patients
Santos-Garcia, D, Fonticoba, TD, Bartolome, CC, Alvarado, MCI, Panceiras, MJF, Castro, ES, Canfield, H, Miro, CM, Jesus, S, Aguilar, M, Pastor, P, Planellas, L, Cosgaya, M, Caldentey, JG, Caballol, N, Legarda, I, Vara, JH, Cabo, I, Manzanares, LL, Aramburu, IG, Rivera, MAA, Mayordomo, VG, Nogueira, V, Puente, V, Garcia-Soto, JD, Borrue, C, Vila, BS, Sauco, MA, Vela, L, Escalante, S, Cubo, E, Padilla, FC, Castrillo, JCM, Alonso, PS, Losada, MGA, Ariztegui, NL, Gaston, I, Kulisevsky, J, Estrada, MB, Seijo, M, Martinez, JR, Valero, C, Kurtis, M, de Fabregues, O, Ardura, JG, Redondo, RA, Ordas, C, DiazL, LML, McAfee, D, Martinez-Martin, P, Mir, P. Predictors of the change in burden, strain, mood, and quality of life among caregivers of Parkinson's disease patients. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY. 2022; 37(6)DOI:10.1002/gps.5761. PMID:35633051. IF:4.000(Q2/3D).
01/06/2022
The network structure of cognitive deficits in first episode psychosis patients
Sánchez-Torres A.M., Peralta V., Gil-Berrozpe G.J., Mezquida G., Ribeiro M., Molina-García M., Amoretti S., Lobo A., González-Pinto A., Merchán-Naranjo J., Corripio I., Vieta E., de la Serna E., Bergé D., Bernardo M., Cuesta M.J., Cabrera B., Pons M., Abregú-Crespo R., Rapado-Castro M., Alonso-Solís A., Grasa E., González-Ortega I., Alberich S., de la Cámara C., Saz P., Aguilar E.J., Escartí M.J., Martínez L., Toll A., Gavin P., Varo C., Baeza I., Puig O., Contreras F., Saiz-Masvidal C., Álvarez L.G., Bascarán M.T.B., Fraile M.G., Rabadán A.Z., Sanchez-Pastor L., Rodriguez-Jimenez R., Usall J., Butjosa A., Sarró S., Landín-Romero R., Ibáñez Á., Moreno-Izco L., Balanzá-Martínez V.. The network structure of cognitive deficits in first episode psychosis patients. SCHIZOPHRENIA RESEARCH. 2022; 244DOI:10.1016/j.schres.2022.05.005. PMID:35594732. IF:4.500(Q2/4D).